Global Markets for Bioengineered Protein Drugs
The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.
- An overview of the global market for bioengineered protein drugs.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
- A look at current technologies underlying the market as well as the effects new technologies will have on the market.
- An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
- Profiles of the major companies involved in the production and modification of protein drugs.
The scope of this study involves the bioengineered protein therapeutics used in the pharmaceutical and the biopharmaceutical markets. BCC Research analyzes each market and its applications, regulatory environment, technologies involved, market projections and market shares. The technological issues include all the latest trends, pipeline products and developments. The emerging markets cover countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.
The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes, peptide hormones and blood factors. These products are bioengineered and are produced by recombinant DNA technology. The only blood products considered in this report are recombinant blood products which are derived through the recombinant DNA technology process.
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%.
Modified and engineered antibodies present the largest share of the total global market. In 2006, this sector held almost 56% of the global market. By the end of 2011 its share will drop slightly but not significantly to 54%.
Hormone protein drugs have the largest AAGR through the forecast period, averaging 5.1% through 2011 to reach $11.9 billion by 2011.
In 2002, drug companies sold nearly $33 billion in protein drugs, and they are projected to approach $40 billion in 2003.
Rising at an average annual growth rate (AAGR) of 12.2%, this market is expected to reach $71 billion in 2008.
Replacement proteins constitute the bulk of the market and will rise at an AAGR of 9.8% from $31.4 billion in 2003 to $50 billion in 2008.
Monoclonal antibodies and fusion proteins will rise from $8.5 billion in 2003 to $20.1 billion in 2008.
These products effectively strip market share from older, less effective therapies. Most notably, a number of monoclonal antibodies are in the last stages of clinical trials for the treatment of autoimmune disease and cancer and promise to be blockbuster products.